Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue

Laboratory Investigation

Volumn 84, Issue 1, 2004, Pages 113-121

  Fellenberg, Joerg ^a   Krauthoff, Alexandra ^a   Pollandt, Konstantin ^b   Delling, Guenter ^b   Parsch, Dominik ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cancer; Chemotherapy; Gene expression; Laser microdissection; Osteosarcoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PARAFFIN; ANTINEOPLASTIC AGENT; MESSENGER RNA; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CELL ISOLATION; CONTROLLED STUDY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; LASER MICRODISSECTION; ONCOGENE NEU; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; BONE TUMOR; EVALUATION; GENETICS; IMMUNOHISTOCHEMISTRY; LASER; METABOLISM; MICRODISSECTION; PATHOLOGY; PREDICTION AND FORECASTING; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; LASERS; MICRODISSECTION; OSTEOSARCOMA; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 85047689697     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700006     Document Type: Article

References (39)

1. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
2. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
3. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993;11:449-453.
4. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-1230.
5. Winkler K, Bielack SS, Delling G, et al. Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer Treat Res 1993;62:269-277.
6. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:848-858.
7. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997;44:973-989.
8. Baldini N, Scotlandi K, Serra M, et al. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res 1999;17:629-632.
9. Bargmann CI, Weinberg RA. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci USA 1988;85:5394-5398.
10. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999;112:S53-S67.
11. Bongiorno PF, Whyte RI, Lesser EJ, et al. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J Thorac Cardiovasc Surg 1994;107:590-595.
12. Cirisano FD, Karlan BY. The role of the Her-2/neu oncogene in gynecologic cancers. J Soc Gynecol Invest 1996;3:99-105.
13. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987;235:177-182.
14. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti- HER 2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
15. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 2000;103:57-75.
16. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-1808.
17. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-2788.
18. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77:71-78.
19. Morris CD, Gorlick R, Huvos G, et al. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop 2001;382:59-65.
20. Thomas DG, Giordano TJ, Sanders D, et al. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002;8:788-793.
21. Maitra A, Wanzer D, Weinberg AG, et al. Amplification of the HER2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 2001;92:677-683.
22. Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 2001;14:1277-1283.
23. Zhou H, Randall RL, Brothman AR, et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25:27-32.
24. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
25. Walch A, Specht K, Smida J, et al. Tissue microdissection techniques in quantitative genome and gene expression analyses. Histochem Cell Biol 2001;115:269-276.
26. Lehmann U, Bock O, Glockner S, et al. Quantitative molecular analysis of laser-microdissected paraffin-embedded human tissues. Pathobiology 2000;68:202-208.
27. Fend F, Specht K, Kremer M, et al. Laser capture microdissection in pathology. Methods Enzymol 2002;356:196-206.
28. Goldsworthy SM, Stockton PS, Trempus CS, et al. Effects of fixation on RNA extraction and amplification from laser capture microdissected tissue. Mol Carcinogen 1999;25:86-91.
29. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001;25:409-418.
30. Godfrey TE, Kim SH, Chavira M, et al. Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5′ nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn 2000;2:84-91.
31. Specht K, Richter T, Muller U, et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001;158:419-429.
32. Masuda N, Ohnishi T, Kawamoto S, et al. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res 1999;27:4436-4443.
33. Salzer-Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumors]. Pathologe 1983;4:135-141.
34. Coombs LM, Pigott DA, Sweeney E, et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991;63:601-608.
35. Akslen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995;76:1643-1654.
36. Gancberg D, Lespagnard L, Rouas G, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 2000;113:675-682.
37. Imamichi Y, Lahr G, Wedlich D. Laser-mediated microdissection of paraffin sections from Xenopus embryos allows detection of tissue-specific expressed mRNAs. Dev Genes Evol 2001;211:361-366.
38. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671.
39. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744.